Atherosclerosis Drugs Market (Drug Type - Cholesterol Medications, Beta Blockers, Angiotensin-converting Enzyme Inhibitors, Calcium Channel Blocker, Diuretics, Antiplatelet, and Other Medications; Distribution Channel - Hospital-based Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2027

A recent report published by Infinium Global Research on the atherosclerosis drugs market provides in-depth analysis of segments and sub-segments in the global as well as regional atherosclerosis drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional atherosclerosis drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global atherosclerosis drugs market. According to the report, the global atherosclerosis drugs market is projected to grow at a CAGR of 2% over the forecast period of 2021-2027. The global atherosclerosis drugs market was valued at USD 50 billion in 2021 and is expected to reach USD 57 billion in 2027.

Market Insight

The global atherosclerosis drugs market exhibited strong growth during the forecast period. Atherosclerosis is distinguished by the reducing and hardening of the arteries. During this condition, arteries become blocked by fatty substances, like cholesterol. These substances are called plaques or atheroma. The risks of atherosclerosis increase with age. The deposition of plaque tends to narrow the arterial canal, which ends within the limited flow of blood and oxygen through it. Atherosclerosis commences with damage to the endothelium of arteries resulting in the formation of plaque. This condition is dangerous for vital organs like the cardiac and brain. The danger related to atherosclerosis includes serious cardiovascular and brain diseases. Collectively, these conditions are more common for cardiovascular diseases (CVD) including coronary cardiovascular disease, heart disease, and transitory ischemia. Other risks for atherosclerosis are artery disease, uropathy, and peripheral artery disease.

The rising population worldwide, and thus the growing demand for quality drugs are significant factors driving the expansion of the worldwide migraine drugs market. An increasing number of pipeline studies and therefore the rising involvement of key players in developing the treatment options for atherosclerosis are expected to propel atherosclerosis treatment drugs market growth. Moreover, technological advancement in atherosclerosis treatment procedures is predicted to grow up the atherosclerosis treatments drug market growth. Nano polymer therapy is the treatment of atherosclerosis that stops heart disease with a replacement biomedical polymer that reduces plaque and inflammation within the vascular system. E-selectin-targeting polymer helps to cut back existing plaque and impedes further plaque formation. However, the side effects related to atherosclerosis drugs and therefore the limited efficacy of the drugs are expected to hamper atherosclerosis market growth. Furthermore, statins are related to an increased incidence of diabetes and hemorrhage. Statins tend to extend the chance of type 2 diabetes during a dose-dependent mode.

Among the regions, North America holds the largest market share of the Atherosclerosis Drugs Market. The increasing number of patients, growing investments in R&D activities, and therefore the establishment of technically advanced research centers will contribute to the Atherosclerosis Drugs Market growth within the region. Europe held the second-largest share within the global atherosclerosis drugs market. The expansion of the atherosclerosis drugs market within the region may be attributed to the rise within the prevalence of cardiovascular diseases and strategic developments by key players. However, Asia Pacific accounted for a major share of the worldwide atherosclerosis drugs market in 2018, and this market within the region is predicted to grow at a rapid pace during the forecast period. A rise within the number of individuals tormented by cardiovascular diseases, product approvals, and an increase in awareness about cardiovascular diseases are factors anticipated to fuel the expansion of the atherosclerosis drugs market within the region.

Segment Covered

The report on global atherosclerosis drugs market covers segments such as drug type, and distribution channel. On the basis of drug type, the sub-markets include cholesterol medications, beta blockers, angiotensin-converting enzyme inhibitors, calcium channel blocker, diuretics, antiplatelet, and other medications. On the basis of distribution channel, the sub-markets include hospital-based pharmacies, retail pharmacies, and online pharmacies.

Companies Profiled:

The report provides profiles of the companies in the market such as Pfizer Inc., AstraZeneca, Merck & Co., Inc., Sanofi US, Amgen Inc., Novartis AG, GlaxoSmithKline Plc, Bayer AG, Mylan N.V., and Eli Lilly and Company.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of atherosclerosis drugs market. Moreover, the study highlights current market trends and provides forecast from 2021-2027. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.